Skip to main content
HCPCS J7608 · Level II · Part B drug

J7608: acetylcysteine, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J7608

Billing unit
1 GM
Acetylcysteine non-comp unit
ASP payment limit
$6.398
October 2026; -12.0% vs July 2026
Practitioner MUE
3
MAI 3
OPPS status
SI M
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J7608 is the Level II code for Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram, billed per 1 GM. The Medicare Part B ASP payment limit for October 2026 is $6.398 per billing unit, down 12.0% from July 2026. The practitioner MUE allows up to 3 units per date of service (MAI 3), so a full 3-unit day is $19.19 at the current limit. Under OPPS it carries status indicator M. J7608 is billed in units of 1 GM; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names acetylcysteine: J0132 (billed per 100 mg). The ASP crosswalk maps 17 NDCs to it, sold as Acetylcysteine by Pfizer Inc, American Regent, Inc., Cameron Pharmaceuticals, LLC. No current Billing and Coding Article lists J7608, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J7608 at $6.398 per 1 GM for October 2026, derived from manufacturer average sales price plus 6%, compared with $7.274 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J7608
QuarterPayment limitPerCoinsurance
October 2026$6.3981 GM20%
July 2026$7.2741 GM—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 17 NDCs from 5 labelers to J7608. Report the NDC in the claim's drug segment and bill the number of J7608 units that equals the quantity administered divided by 1 GM; the last column gives units per full package.

NDCs that crosswalk to J7608
NDCDrug nameLabelerPackage sizeBilling units / package
00409-3307-03AcetylcysteinePfizer Inc30 × 39
00409-3308-03AcetylcysteinePfizer Inc30 × 318
00517-7504-25AcetylcysteineAmerican Regent, Inc.4 × 2510
00517-7604-25AcetylcysteineAmerican Regent, Inc.4 × 2520
42494-0435-25AcetylcysteineCameron Pharmaceuticals, LLC4 × 2510
42494-0436-25AcetylcysteineCameron Pharmaceuticals, LLC4 × 2520
63323-0690-30AcetylcysteineFreseniUS Kabi USA, LLC30 × 318
63323-0690-44AcetylcysteineFreseniUS Kabi USA, LLC30 × 318
63323-0691-30AcetylcysteineFreseniUS Kabi USA, LLC30 × 39
63323-0692-10AcetylcysteineFreseniUS Kabi USA, LLC10 × 36
63323-0693-10AcetylcysteineFreseniUS Kabi USA, LLC10 × 33
63323-0694-04AcetylcysteineFreseniUS Kabi USA, LLC4 × 2520
63323-0694-44AcetylcysteineFreseniUS Kabi USA, LLC4 × 2520
63323-0695-04AcetylcysteineFreseniUS Kabi USA, LLC4 × 2510
70069-0018-25AcetylcysteineSomerset Pharma, LLC4 × 2510
70069-0019-25AcetylcysteineSomerset Pharma, LLC4 × 2520
70069-0020-03AcetylcysteineSomerset Pharma, LLC30 × 318

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J7608. For practitioners the limit is 3 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J7608 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services33 Date of Service Edit: ClinicalClinical: Data
Facility outpatient hospital03 Date of Service Edit: ClinicalCMS Policy
DME supplier2223 Date of Service Edit: ClinicalPublished Contractor Policy

MUE for J7608 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

Medicaid NCCI differs: the 2026 Q4 Medicaid MUE for J7608 is 3 units for outpatient hospital claims (Medicare: 0) and 74 units for DME supplier claims (Medicare: 222). Compare both programs in the MUE lookup or read how Medicaid NCCI differs from Medicare.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J7608 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J7608 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J7608 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J7608 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Local coverage policies that list J7608

1 active Local Coverage Determination lists J7608 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J7608 carries status indicator M. The OPPS status indicator reference explains how status M is paid.

Common denials for J7608 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J7608

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J7608

What does HCPCS code J7608 describe?

J7608 is defined by CMS as "Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram". Each billing unit represents 1 GM, so the units reported on the claim must equal the dose administered divided by that unit.

Is J7608 a CPT code?

No. J7608 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as acetylcysteine; CPT codes are five-character codes maintained by the AMA. On a Part B claim J7608 reports the drug itself in 1 gm units, and the administration is billed on its own line.

What is the Medicare reimbursement for J7608 in October 2026?

The ASP-based payment limit is $6.398 per 1 GM, with 20% beneficiary coinsurance. The July 2026 limit was $7.274. Commercial payers use their own fee schedules.

How many units of J7608 can be billed per day?

The practitioner Medically Unlikely Edit is 3 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). The facility outpatient MUE is 0. MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Data" as the rationale.

Which NDCs map to J7608?

The October 2026 ASP crosswalk lists 17 NDCs from 5 labelers: Acetylcysteine (Pfizer Inc); Acetylcysteine (American Regent, Inc.); Acetylcysteine (Cameron Pharmaceuticals, LLC); Acetylcysteine (FreseniUS Kabi USA, LLC). For example NDC 00409-3307-03 (package size 30) equals 9 billing units of J7608.

Does J7608 have NCCI bundling edits?

No active practitioner PTP pairs list J7608 as a column-1 or column-2 code in the v323r0 release.

J7608 vs J0132: what is the difference?

Both are HCPCS Level II codes whose descriptor names acetylcysteine. What sets J0132 apart: billed per 100 mg. J7608 is billed per 1 gm, limit $6.398, MUE 3; J0132 is billed per 100 mg, limit $0.499, MUE 12. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.